Hyperfine, Inc. has reported its financial results for the first quarter of 2025. The company's revenues for this period were $2.1 million, a decrease from $3.3 million in the first quarter of 2024. Hyperfine sold six commercial Swoop® systems during the first quarter of 2025. The gross margin for this quarter was $0.9 million, compared to $1.3 million in the same period last year, with the gross margin percentage slightly increasing to 41.3% from 41.1% in 2024. The net loss for the first quarter of 2025 was $9.4 million, which shows an improvement from the $9.8 million net loss reported in the first quarter of 2024. Hyperfine's management has provided financial guidance for 2025, projecting revenue for the first half of the year to be in the range of $5 to $6 million. They also anticipate an annual revenue growth of 10% to 20% over 2024 and expect cash burn for the full year 2025 to be approximately $25 to $28 million, representing a 31% decline at the midpoint compared to 2024. In terms of business updates, Hyperfine has submitted its next-generation Swoop® system technology to the U.S. Food and Drug Administration. Additionally, the company has started patient enrollment in the NEURO PMR study, which is aimed at evaluating the use of AI-powered portable MRI in neurology offices, with completion expected by the end of the third quarter of 2025. Hyperfine is also focusing on expanding its pipeline, including promising early opportunities in the neurology office setting, and aims to diversify its revenue profile starting in the second half of 2025.